What the FDA labels say about taking them together
Atorvastatin and sarilumab
Sarilumab's FDA label of February 27, 2026 names atorvastatin in its drug interactions section; the atorvastatin labels PlainMeds reads (2) do not name sarilumab. The sarilumab label: “Exercise caution when co-administering KEVZARA with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. …”
Check it at the source: the atorvastatin FDA label on DailyMed (effective April 15, 2024, Viatris Specialty LLC); the sarilumab FDA label on DailyMed (effective February 27, 2026, Sanofi-Aventis U.S. LLC).
What does the atorvastatin label say about sarilumab?
Atorvastatin's label (effective April 15, 2024) and its 1 other brand-application label do not name sarilumab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Lipitor), NDA020702 (Upjohn), as published by Viatris Specialty LLC, effective April 15, 2024 (SPL set a60cc18b-0631-4cf0-b021-9f52224ece65), via openFDA; the full label on DailyMed
What does the sarilumab label say about atorvastatin?
Sarilumab label, drug interactionsExercise caution when co-administering KEVZARA with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc. The effect of KEVZARA on CYP450 enzyme activity may persist for several weeks after stopping therapy [see Clinical Pharmacology (12.3) ].
Source: FDA drug label (KEVZARA), Sanofi-Aventis U.S. LLC, effective February 27, 2026 (SPL set 827bc01c-d379-4266-a18c-c7f904b76af3), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atorvastatin | Sarilumab | |
|---|---|---|
| Labeled for | High cholesterol, Angina, High triglycerides, Heart attack and coronary artery disease | Rheumatoid arthritis |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.0228 per tablet 10 mg tablet | $2,075.30 per mL 200 mg/1.14 mL pen injection |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once